IVI Signs with Inviragen to Develop Dengue Fever Vaccine

The International Vaccine Institute and Inviragen announce a collaboration to accelerate development of a dengue vaccine.

The International Vaccine Institute (IVI) and US firm Inviragen have signed a collaboration agreement to develop a vaccine for dengue fever.

The move follows Seoul-based IVI’s launch of the Dengue Vaccine Initiative (DVI) at the beginning of the year, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization.

The DVI received a US$6.9m grant from the Bill & Melinda Gates Foundation and aims to accelerate the development of safe, affordable and broadly protective vaccines to combat dengue fever.

At least 2.5 billion people, or two-fifths of the world’s population, are at risk of contracting dengue, a mosquito-borne infection that cau